Abstract
Indolent T-lymphoblastic proliferation (iT-LBP) is a rare, non-clonal, extrathymic lymphoid proliferation with an immature T cell phenotype, indolent clinical course, and excellent prognosis. Although their pathogenesis is unclear, they are reported to be associated with Castleman disease, follicular dendritic cell tumors/sarcomas, angioimmunoblastic T cell lymphoma, hepatocellular carcinoma (HCC), myasthenia gravis, and acinic cell carcinoma. There are around 51 reported cases of iT-LBP in the literature. Recognition and accurate diagnosis of this entity is critical as it shares morphologic and immunophenotypic features with an aggressive malignancy—acute T cell leukemia/lymphoma (T-ALL). IT-LBP in HCC post-liver transplant and in metastatic sites has not been reported in the literature. Two case reports of patients presenting with recurrent and metastatic HCC in post-liver transplant settings are described. A 50-year-old man with an end-stage liver disease with HCC underwent liver transplant. A year later, he developed pulmonary metastasis with associated iT-LBP. A 69-year-old man underwent liver transplant for end-stage liver disease and HCC. Eighteen months later, he developed recurrent HCC in the transplanted liver and omental metastasis; both sites showed HCC with iT-LBP. iT-LBP in both patients expressed TdT, CD3, and CD4 and lacked CD34 and clonal T cell receptor gene rearrangements. On retrospective review, the pre-transplant HCC specimens lacked iT-LBP. We present two cases of iT-LBP associated with HCC in novel settings—in post-liver transplant patients and in recurrent/metastatic sites of HCC. In addition, a comprehensive literature review of clinical, histological, and immunophenotypic characteristics of reported cases of iT-LBP is presented.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Velankar MM, Nathwani BN, Schlutz MJ, Bain LA, Arber DA, Slovak ML, Weiss LM (1999) Indolent T-lymphoblastic proliferation: report of a case with a 16-year course without cytotoxic therapy. Am J Surg Pathol 23(8):977–981. https://doi.org/10.1097/00000478-199908000-00017
Ohgami RS, Arber DA, Zehnder JL, Natkunam Y, Warnke RA (2013) Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma. Adv Anat Pathol 20(3):137–140. https://doi.org/10.1097/PAP.0b013e31828d17ec
Eun S, Jeon YK, Jang JJ (2010) Hepatocellular carcinoma with immature T-cell (T-lymphoblastic) proliferation. J Korean Med Sci 25(2):309–312. https://doi.org/10.3346/jkms.2010.25.2.309
Ohgami RS, Zhao S, Ohgami JK, Leavitt MO, Zehnder JL, West RB, Arber DA, Natkunam Y, Warnke RA (2012) TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 36(11):1619–1628. https://doi.org/10.1097/PAS.0b013e318264e223
Pilozzi E, Müller-Hermelink HK, Falini B, de Wolf-Peeters C, Fidler C, Gatter K, Wainscoat J (1999) Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 188(3):267–270. https://doi.org/10.1002/(SICI)1096-9896(199907)188:3%3c267::AID-PATH357%3e3.0.CO;2-N
Wang ZM, Xiao WB, Zheng SS, Sun K, Wang LJ (2006) Hepatocellular carcinoma with indolent T-lymphoblastic proliferation. Leuk Lymphoma 47(11):2424–2426. https://doi.org/10.1080/10428190600822151
Kong M, Wang Z, Teng X, Xu L, Liu J, Jiang C, Teng L (2018) Hepatic carcinoma with indolent T-lymphoblastic proliferation (iT-LBP). Int J Clin Exp Pathol 11(3):1674–1678
Brar N, Butzmann A, Kumar J, Peerani R, Morgan EA, Grigoriadis G, Kumar B, Tatarczuch RM, Warnke RA, Ohgami RS (2020) LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations. Histopathology 77(6):984–988. https://doi.org/10.1111/his.14176
Kim WY, Kim H, Jeon YK, Kim CW (2010) Follicular dendritic cell sarcoma with immature T cell proliferation. Hum Pathol 41(1):129–133. https://doi.org/10.1016/j.humpath.2009.05.014
Jevremovic D, Roden AC, Ketterling RP, Kurtin PJ, McPhail ED (2016) LMO2 is a specific marker of T-lymphoblastic leukemia/lymphoma. Am J Clin Pathol 145(2):180–190. https://doi.org/10.1093/ajcp/aqv024
Sato K, Ohtsuka K, Hasegawa K, Yamagiwa S, Watanabe H, Asakura H, Abo T (1995) Evidence for extrathymic generation of intermediate T cell receptor cells in the liver revealed in thymectomized, irradiated mice subjected to bone marrow transplantation. J Exp Med 182(3):759–767. https://doi.org/10.1084/jem.182.3.759
Shimizu T, Bannai M, Kawamura H, Yamamoto S, Oya H, Maruyama S, Minagawa M, Kawamura T, Watanabe H, Hatakeyama K, Abo T (2000) Organ specificity of c-kit+ lymphoid precursors in the liver, thymus, and bone marrow. Eur J Haematol 64(6):416–425. https://doi.org/10.1034/j.1600-0609.2000.90158.x
Shimizu T, Sugahara S, Oya H, Maruyama S, Minagawa M, Bannai M, Hatakeyama K, Abo T (1999) The majority of lymphocytes in the bone marrow, thymus and extrathymic T cells in the liver are generated in situ from their own preexisting precursors. Microbiol Immunol 43(6):595–608. https://doi.org/10.1111/j.1348-0421.1999.tb02446.x
Strauchen JA (2001) Indolent T-lymphoblastic proliferation: report of a case with an 11-year history and association with myasthenia gravis. Am J Surg Pathol 25(3):411–415. https://doi.org/10.1097/00000478-200103000-00018
Qian YW, Weissmann D, Goodell L, August D, Strair R (2009) Indolent T-lymphoblastic proliferation in Castleman lymphadenopathy. Leuk Lymphoma 50(2):306–308. https://doi.org/10.1080/10428190802645079
Yang F, Liu T, Zhao H, Hu Z, Xiao L, Liu Y, Wang X, Li Z (2014) Indolent T-lymphblastic proliferation: report of a case involving the upper aerodigestive tract. Int J Clin Exp Pathol 7(9):6350–6356
Quesada AE, Young KH, Medeiros LJ, Thakral B (2018) Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease. Pathology 50(3):351–352. https://doi.org/10.1016/j.pathol.2017.09.017
Chen J, Feng J, Xiao H, Ma Q, Chen Z (2019) Indolent T-lymphoblastic proliferation associated with Castleman disease and low grade follicular dendric cell sarcoma: report of a case and review of literature. Int J Clin Exp Pathol 12(4):1497–1505
Yasuda H, Tsutsui M, Ota Y, Tanaka M, Komatsu N (2018) Indolent T-lymphoblastic proliferation concomitant with acinic cell carcinoma mimicking T-lymphoblastic lymphoma: case report and literature review. Histopathology 72(5):862–866. https://doi.org/10.1111/his.13433
Ohgami RS, Sendamarai AK, Atwater SK, Liedtke M, Fleming MD, Natkunam Y, Warnke RA (2014) Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression. Am J Surg Pathol 38(9):1298–1304. https://doi.org/10.1097/PAS.0000000000000197
Kansal R, Nathwani BN, Yiakoumis X, Moschogiannis M, Sachanas S, Stefanaki K, Pangalis GA (2015) Exuberant cortical thymocyte proliferation mimicking T-lymphoblastic lymphoma within recurrent large inguinal lymph node masses of localized Castleman disease. Hum Pathol 46(7):1057–1061. https://doi.org/10.1016/j.humpath.2015.03.007
Walters M, Pittelkow MR, Hasserjian RP, Harris NL, Macon WR, Kurtin PJ, Rech KLG (2018) Follicular dendritic cell sarcoma with indolent T-lymphoblastic proliferation is associated with paraneoplastic autoimmune multiorgan syndrome. Am J Surg Pathol 42(12):1647–1652. https://doi.org/10.1097/PAS.0000000000001158
Chauveau B, Le Loarer F, Bacci J, Baylac F, Dubus P, Ling C, Parrens M (2019) Maladie de Castleman localisée avec prolifération lymphoblastique T indolente [Indolent T-lymphoblastic proliferation in association with localized Castleman disease: a case report]. Ann Pathol 39(1):29–35. https://doi.org/10.1016/j.annpat.2018.09.003
Moughames E, Kiess AP, Akst LM, Azar A (2019) Sirolimus for the treatment of airway obstruction due to indolent T-lymphoblastic proliferation. Case Reports in Immunology 2019:1724083. https://doi.org/10.1155/2019/1724083
Yuanyuan Z, Jianlan X, Yanlin Z, Xiaoge Z (2022) Indolent T-lymphoblastic proliferation: a report of three cases. Virchows Archiv : An Int J Pathol 480(5):1121–1126. https://doi.org/10.1007/s00428-021-03184-5
Woo CG, Huh J (2015) TdT+ T-lymphoblastic proliferation in Castleman disease. J Pathol Transl Med 49(1):1–4. https://doi.org/10.4132/jptm.2014.11.17
Hartert M, Ströbel P, Dahm M, Nix W, Marx A, Vahl CF (2010) A follicular dendritic cell sarcoma of the mediastinum with immature T cells and association with myasthenia gravis. Am J Surg Pathol 34(5):742–745. https://doi.org/10.1097/PAS.0b013e3181d7a2ee
Fromm JR, Edlefsen KL, Cherian S, Wood BL, Soma L, Wu D (2020) Flow cytometric features of incidental indolent T lymphoblastic proliferations. Cytometry B Clin Cytom 98(3):282–287. https://doi.org/10.1002/cyto.b.21845
Funding
This study was not supported by any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
N/A.
Informed consent
N/A.
Consent for publication
N/A.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ghezavati, A., Liang, C.A., Mais, D. et al. Indolent T-lymphoblastic proliferation involving hepatocellular carcinoma—presentation in novel settings and comprehensive review of literature. J Hematopathol 16, 167–175 (2023). https://doi.org/10.1007/s12308-023-00554-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12308-023-00554-7